New blood thinner may simplify stroke prevention after heart surgery

NCT ID NCT03702582

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested whether a newer blood thinner, rivaroxaban (Xarelto), is as safe and effective as the older drug warfarin for preventing strokes in people who develop atrial fibrillation after heart surgery. About 100 adults who had open-heart surgery and then experienced a new irregular heartbeat were randomly assigned to receive either rivaroxaban or warfarin. The main goal was to see if rivaroxaban could shorten hospital stays while still preventing strokes and avoiding major bleeding.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Rivaroxaban (Xarelto) and warfarin (Coumadin)
What this could lead to
If rivaroxaban works as well as warfarin, it could offer a simpler, more convenient option for preventing strokes after heart surgery.
What could go wrong
This is a small, completed trial with only 100 participants, so results may not apply to everyone. Both drugs carry a risk of serious bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.